With respect to chemotherapy, pemetrexed is regarded as the preferred drug for advanced NSCLC as neoadjuvant and adjuvant therapy for its therapeutic benefit and good tolerability [17, 18], even in patients with brain metastases [19].﻿ Recently, clinical evidence further revealed the potential of pemetrexed-EGFR TKIs combination. Here, EGFR is linked to non-small cell lung carcinoma.